SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " Vaccine " 1,087 found 🔀 AI-powered Shuffle
U.S. Restores Some Vaccine and Health Aid to Unicef, Gavi and World Food Programme
The amount is still far below what the U.S. spent previously on humanitarian and health aid, but resumes the flow of money for key efforts to fight malnutrition and disease.
Jewish Tulsa, Tulsa Health Department host free seminar on vaccine hesitancy
Jewish Tulsa, Tulsa Health Department host free seminar on vaccine hesitancy.
No cure, no vaccine: Experts warn of rare Bourbon virus after first NY case
A Long Island patient was hospitalized after researchers confirmed the first Bourbon virus case in New York, transmitted by the common lone star tick.
Pediatricians and health officials are sidestepping Trump's CDC on vaccine advice
The rupture of scientific trust in the Atlanta-based CDC has put many pediatricians and health officials in a bind, as they no longer turn to the U.S.'s preeminent public health agency and instead search for ways to fill the information gap.
Does public health *need* MAHA?
Last week, our friend Dr. Craig Spencer sparked an ongoing volatile discussion with his Atlantic article “Public Health Needs MAHA.” Some have come out in strong dissent, others are cheering, and others are simply lamenting that we find ourselves in such a divided world to begin with. We will dare to dip our toes in these controversial waters, too. Does public health need MAHA? We think in some ways yes, and in other ways, no. MAHA leaders versus the everyday MAHA supporter The vitriol in this debate mostly comes from one collapsed distinction: the leadership of MAHA is not necessarily the same as the people who support it. Say “MAHA” and most people picture RFK Jr. Fair enough, as he coined the term and holds most of the power. And, yes, some MAHA followers treat Kennedy as something close to a saint. But talk to the grassroots, and it’s not a monolith. They’re Republicans, Democrats, and Independents. People who distrust vaccines and vaccine supporters. It’s a wide, eclectic coalition. The data backs this too: 4 in 10 Americans support the movement—that’s a lot of people! But according to polls, vaccines and medical choice (the issues most tied to Kennedy personally) are cited by only 4% as their reason for supporting the movement. For many, the motivations are much broader. Many MAHA supporters are signing up for the idea that “something needs to change” with health in this country. They’re asking good-faith questions about corporate influence on our health systems, health care costs, nutrition, chemicals, and clean air and water. These are all questions that plenty of public health professionals recognize as legitimate and also care about very deeply. Blurring the lines between the leadership and grassroots does real damage in two important ways: It hands the 4 in 10 exactly the narrative already fed—that the health ecosystem doesn’t listen, doesn’t care, and paints every critic with the same brush. It gives the actual bad actor more power. RFK Jr. has done irreparable damage and can’t be trusted. What the MAHA movement gets right A healthy population is something the public health field was literally built on, and many of these topics are things we have dedicated our lives to. Yet the MAHA movement has captivated nearly half the country in a way the public health establishment has failed to achieve. So that means MAHA is doing something right. Some of it may be timing (after a Covid-19 pandemic and deep frustration and mistrust with institutions). The movement also does three other things really well: 1. It gives a new, louder voice to system failures. While MAHA is not a monolith, one theme stays consistent across their stories: the system failed them. For some, it was the system that flooded their communities with opioids and then walked away. For others, it was the system that let their business collapse during Covid with no safety net in sight. For others still, it was the system that failed to help them manage a complex chronic illness, bouncing them from physician to physician without any real answers. And in many ways, our health ecosystems are failing Americans. Why are medical bills so incomprehensible? Why do some kids get a healthy school lunch and others don’t? Why do an epidemiologist and a MD/PhD student have to start newsletters in the middle of the biggest public health emergency in a century, just so people can get straight information? Because the systems failed. This deep-seated frustration driving many Americans to search for solutions elsewhere needs to be recognized. 2. MAHA has brilliant comms central to their efforts. MAHA figured out something most health institutions still have not: the information landscape changed. It’s participatory now, not top-down; influence runs through many nodes in a community, not one institution; and storytelling and telling audiences “what you really think” moves people more than data dumps do. MAHA goes where audiences are listening, using podcasts, social media, and memes in ways most health institutions would scoff at—but it works. 3. They are very good at organizing. A MAHA meeting feels like a rally: energy, speakers, music, and most importantly, an action for everyone. Someone’s writing the next policy brief, someone’s seeding a narrative, someone knows the next legislative deadline, someone’s sending the text messages for a campaign. None of this is new (ask the civil rights movement), but MAHA knows it works and has capitalized on it. What MAHA gets wrong This list could be much longer, and this newsletter has spent a lot of time covering it, but here are a few things: Poor use of scientific evidence. This is the fundamental problem with many MAHA policies: the hype outpaces the science, and experts are often villainized for pointing this out. MAHA leadership has traded real solutions for cheap wins. For example, instead of taking on the powerful food industry and passing real reforms, it has celebrated french fries made of beef tallow and taken out artificial dyes from still very sugary children’s cereal. These changes won’t move the needle on America’s diet. MAHA leadership has tried to dismantle vaccine access in the U.S. While many MAHA supporters emphasize other issues, the effort to change vaccine policy has become MAHA’s signature effort. This is not surprising given RFK Jr.’s extensive track record campaigning against vaccines. It has rallied behind the wrong leader. RFK Jr. has a decades-long track record of villifying doctors, scientists, and public health workers, well before he became HHS secretary. He is known for his decades-long work sowing distrust in vaccines as well as life-saving treatments like antiretroviral therapy for HIV. This is not a serious person who can move the needle on health in the U.S, and he has already done serious damage. Public health needs more than defense Defending the evidence is absolutely necessary so health in the U.S. doesn’t move further backward. The public health establishment is very good at defense. The problem is this defense often sounds like defending the status quo, which has failed many people. Public health needs to offer an alternative to RFK Jr.’s MAHA—one that is rooted in evidence, truly listens to and addresses people’s frustrations, and has innovative solutions and the courage to change the systems. How do we get there? Find common ground. Do you know what most people care most about? The abysmal cost of healthcare. Start there. Fight for the human loudly. Too often, communications and engagement center on science with a capital S, funding mechanisms, or the CDC/FDA/NIH. Not the person. So the public doesn’t see themselves in it. Instead, they see people fighting for the very powerful systems that they feel negatively impact their health and well-being. Let the public feel and hear that you see their frustrations, you get it, and you’re fighting for them within the system. Recognize when pro-science messages are alienating people. Facts absolutely matter, but angrily venting only alienates people further. Our friend Elisabeth Marnik recently wrote a New York Times article about her experience growing up unvaccinated and how listening and empathetic conversation are the only ways to reach people that really work (a position backed by communication science). Her comments section was full of hateful comments from pro-vaccine individuals attacking her for daring to suggest we approach vaccine-hesitant individuals with empathy. It is possible to both stand firm behind scientific evidence and empathize with people who don’t trust it. Lean into politics smartly. Often, public health has shied away from politics: Don’t touch it, lest you get burned. But this fails to recognize that the third rail is what fuels the train: who is elected determines our budgets, our priorities, and our authority. Being political means being very savvy in strategy on both sides of the aisle, knowing your audience, and recognizing that political capital is as scarce as financial resources and needs to be allocated accordingly. Bottom line So does public health need MAHA? That’s not really the right question. Public health has a responsibility not to dismiss 40% of the country who feel heard by this movement and are frustrated that the system has failed them. And it has a responsibility to stick to the evidence and recognize MAHA leadership for what it is: a danger to our nation’s health. Both can, and should, be done. Love, YLE and KP A big thanks to Craig Spencer, who had the courage to put his neck out there to start a much-needed discussion at such a critical moment—one that is determining the identity of an entire field. Kristen Panthagani, MD, PhD is completing an emergency medicine residency and research fellowship focusing on health literacy and communication. In her free time, she writes the newsletters You Can Know Things debunking health myths and rumors and The Public Health Roundup. Views expressed belong to KP, not her employer. Your Local Epidemiologist (YLE) comprises a team of experts, ranging from physicians to immunologists to epidemiologists to nutritionists, working together with one goal: to “translate” ever-evolving public health science so that people are well-equipped to make evidence-based decisions. The YLE suite of newsletters reaches over 475,000 people across more than 132 countries. This newsletter is free to everyone, thanks to the generous support of fellow YLE community members. To support the effort, subscribe or upgrade below: Subscribe
The shaky health leadership reboot
Controversial vaccine policymaking appears to be back on the table.
Arkansas Health Department offers back-to-school vaccine clinics, whooping cough focus
Hamilton County families urged to get school vaccines before classes begin
With the first day of school approaching, the Hamilton County Health and Social Services Division is encouraging parents to schedule their children's required v
Health emergency preparedness nominee advances on party lines - Live Updates
Sean Kaufman had previously made controversial comments about vaccines and disparaged the CDC, throwing his nomination into question.
Ebola outbreak nears milestone, but vaccine is close
Medicaid work rules, FTC sues Hims, and more health news from Morning Rounds
Pediatricians and health officials are sidestepping Trump's CDC on vaccine advice
The Trump administration's upending of years of vaccine advice puts many pediatricians in a quandary. Some are steering patients away from the CDC to other authoritative websites, including their own.
Merck, Wellcome partner with global health group to make Ebola vaccine for clinical trials
Hilleman Laboratories, a Singapore-based joint venture between Merck and the global charity Wellcome, is gearing up to manufacture doses of a promising experimental vaccine against the rare Bundibugyo strain of Ebola responsible for a fast-spreading outbreak in the Democratic Republic of Congo.
Merck, Wellcome partner with global health group to make Ebola vaccine for clinical trials
CHICAGO, July 30 (Reuters) - Hilleman Laboratories, a Singapore-based joint venture between Merck and the global charity Wellcome, is gearing up to manufacture doses of a promising experimental vaccin...
Trump administration to dispense $600M for vaccines RFK Jr. held up
The Health secretary said the group Congress had directed the money, to vaccinate children in poor countries, was using dangerous shots. The administration says it has secured reforms.
US lawmakers press Health Secretary Robert F. Kennedy Jr. on vaccine settlement
The letter notes that Merck earlier this year agreed to pay $50 million to settle litigation over Gardasil.
US lawmakers press Health Secretary Robert F. Kennedy Jr. on vaccine settlement
A group of U.S. senators has asked Health Secretary Robert F. Kennedy Jr. to disclose whether his family stands to profit from a recent legal settlement involving Merck's Gardasil vaccine, according to a letter reviewed by Reuters.
Exposure to measles possible at two Portland health care sites
Measles exposure alert in Portland: officials say visitors to Randall’s Children’s Hospital ER and Providence St. Vincent may have been exposed on July 23 to 28.
The Key Points of Tension Between Trump and RFK Jr. Over Vaccines
Takeaways from The Wall Street Journal’s coverage of Trump’s push on vaccines and autism.
How vaccine skeptics use storytelling to create powerful and medically inaccurate messaging
Recognizing the stories behind people’s concerns with vaccines can help public health advocates build a more inclusive approach to healthcare.
Delaware County, Pennsylvania, launches mobile health clinic to offer measles vaccines
Free vaccines, sports physicals available as central Wisconsin students prepare for school
Wausau Pilot & Review WAUSAU, Wis. — Central Wisconsin health departments are offering back-to-school vaccination clinics for uninsured children and
Congo Ebola death toll tops 1,400 as vaccine trials start
DR Congo's Ebola outbreak has continued to grow, with confirmed infections reaching 3,200 and a fatality rate of nearly one in two. Scientists are racing to test the first vaccines against the rare Bundibugyo strain.
It looks like Sen. Bill Cassidy is hurting public health again
The Louisiana senator and physician has pledged support for Trump's nominee for CDC director based on assurances on vaccines. He did the same with RFK Jr.
Measles on the rise in California
Measles cases over past six months have doubled from the same period last year
Measles exposure location confirmed at Gresham urgent care
Measles exposure alert in Gresham: Multnomah County says visitors to Legacy Go Health Urgent Care on NE Glisan July 23, 4 to 8 p.m., may have been exposed.
The viral online attack on Pittsburgh doctors that sparked a national debate over vaccines
One by one, the faces of the doctors splashed across the screen in a dramatic video created to reach thousands of viewers with a simple message. The HPV...
What experts are saying as Ebola outbreak in Congo and Uganda kills more than 1,000 people
The fastest-growing Ebola outbreak in history has killed more than 1,000 people in eastern Congo as health officials race to contain a virus with no approved vaccine or treatment.
Vote on CDC nominee clinched with change to CDC’s website on vaccines and autism
The Senate’s health committee pushed back a vote to advance two top health care nominations but indicated that one, the pick to lead the US Centers for Disease Control and Prevention, would win the necessary votes.
Cassidy shifts on CDC nominee, citing change to disputed autism page
But the page’s core claim still suggests a long debunked link between vaccines and autism.
Vote on key federal health nominee delayed amid questions over vaccine views
Sean Kaufman, nominated to run ASPR, has a track record of questioning the safety of vaccines.
Vote on health emergency preparedness nominee delayed - Live Updates
Sean Kaufman's history of questioning vaccine safety took center stage at his confirmation hearing last week.
Health department to hold free flood-recovery vaccine clinic Friday at Wesleyan
The Upshur-Buckhannon Health Department will offer free Tdap and hepatitis A vaccines beginning at 10 a.m. Friday, July 24, at West Virginia Wesleyan College for anyone who was in floodwater or is helping with cleanup.
Bay Area health officials urge vaccinations as measles cases continue to surge nationwide
Bay Area health officials are urging parents and international travelers to follow vaccination guidelines to prevent measles infections over the summer as
US Health Secretary Kennedy Says CMS Is Pausing Medicaid Payments to California and Minnesota
July 21 (Reuters) - The Trump administration is pausing over $1 billion in Medicaid payments to California and Minnesota "because of suspected fraud and noncompliance," U.S. Health Secretary Robert F. Kennedy, Jr. said on Tuesday. "If those states want that money they need to ...
FDA is still focused on lettuce supplier as source of parasite, despite faulty test result
Federal health officials said Monday they remain focused on lettuce from Taylor Farms as the source of a multistate outbreak of a diarrhea-causing parasite, despite inaccurate test results that the government briefly publicized over the weekend.
HHS vaccine committee quietly gets new charter
Lax clinical oversight for online GLP-1 prescriptions, proposed financial help for people who want to quit smoking, and more health news
New Mexico health officials encourage parents to update student vaccinations
State health officials reported that about 95% of students statewide received school-required vaccines last year
Trump's CDC Nominee Praises Vaccines, Without Vowing Independence From RFK Jr.
By Rachel Spears and KFF Health News HealthDay ReportersMONDAY, July 20, 2026 (HealthDay News) — Dr. Erica Schwartz, President Donald Trump’s nominee to lead the U.S. Centers for Disease Control and Prevention, expressed support for vaccines — including mRNA-based COVID shots — in a Senate hearing,
Inside RFK Jr.’s push to dismantle decades of U.S. vaccine policy
Robert F. Kennedy Jr. has brought a series of once-unthinkable public-health proposals to the highest levels of the Trump administration.
CDC Director Nominee Erica Schwartz Grilled by Senators About Vaccines and Political Pressure
A former deputy surgeon general, Schwartz vowed during her confirmation hearing to “never compromise on the science.”
Health emergency preparedness nominee walks back comments skeptical of vaccine safety - Live Updates
Sean Kaufman, the White House nominee for the health department's assistant secretary for preparedness and response, said the shots were safe after expressing vaccine skepticism online.
Cook County Public Health Offers Back-to-School Vaccinations at Suburban Cook County Community Events - Cook County Department of Public Health
Parents can get their children vaccinated for the upcoming school year, right on time for National Immunization Awareness Month in August. Cook County Department of Public Health (CCDPH) is providing back-to-school immunizations at no cost for the 2026-27 school year to children ages 6 months to 18 years old, regardless of immigration or insurance status, now through mid-October.
Senators Question Trump’s CDC Nominee Dr. Erica Schwartz on Vaccines
Dr. Erica Schwartz said she would uphold science amid lawmaker questions over vaccine policy and Robert F. Kennedy Jr.
Trump's CDC pick could have easier path than other nominees
That doesn't mean controversies around vaccines and public health are over.
Trump’s Latest Nominee for C.D.C. Director Will Face Senate Panel
Dr. Erica Schwartz supports vaccines and is seen as a mainstream choice to lead an agency that has been a target of Health Secretary Robert F. Kennedy Jr.’s efforts to change federal immunization policies.
What to watch for as senators question CDC nominee Erica Schwartz
Schwartz is set for a confirmation hearing along with Sean Kaufman, a pick for another key HHS role. Vaccines will almost certainly be a topic.
What to watch for as senators question CDC nominee Erica Schwartz
Schwartz is set for a confirmation hearing along with Sean Kaufman, a pick for another key HHS role. Vaccines will almost certainly be a topic.
Pa. health department launches dashboard of reported measles cases in the state
The database will be updated three times per week with details about the county, age and hospitalization status of each case.
Vaccine skeptic Dr. Ryan Cole to stay on board of Idaho’s largest public health district
Dr. Ryan Cole, an Idaho pathologist who has been a vocal critic of COVID vaccines, is staying on the Central District Health board.
Federal funding and science doubled life expectancy. We can’t do more with less.
We are at dangerous risk of turning back the clock on the strides we’ve made in public health.
Azerbaijan health officials deny mumps epidemic in Baku
The Ministry of Health of the Republic of Azerbaijan reports posts have been circulating on social networks about the widespread spread of epidemic mumps in Baku do not reflect the current epidemiological situation. Health officials say the epidemiological situation of mumps in the country is stable. The registered cases of infection consist of individual sporadic cases, no epidemics or mass spread have been recorded. The current situation is constantly under epidemiological surveillance by relevant medical institutions, and the necessary preventive and counter-epidemic measures are consistently implemented. Epidemic mumps is observed more often among unvaccinated or incompletely vaccinated individuals. The disease is transmitted mainly by airborne droplets - during coughing, sneezing and close contact. The incubation period usually lasts 11–23 days. The main symptoms of the disease are fever, swelling and pain in the parotid salivary glands, discomfort when chewing and swallowing, general weakness, headache and loss of appetite. In most cases, mumps is mild and results in complete recovery. However, in rare cases, certain complications may develop in unvaccinated adolescents and adults. Therefore, timely vaccination is of particular importance in preventing the disease. Subscribe to Outbreak News TV on YouTube In accordance with the National Vaccination Schedule in Azerbaijan, the combined measles, mumps, and rubella (MMR) vaccine is administered to children at 12 months of age, with a booster dose at 6 years of age. The MMR vaccine is the most reliable and effective means of protection against mumps. The Ministry of Health recommends that parents check their children’s vaccination status. If for any reason the vaccination has been delayed or missed, it is recommended to contact the medical facility in your area of residence and consult a doctor. To protect yourself from the disease, it is recommended to follow preventive measures such as avoiding close contact with sick people, following personal hygiene rules, washing hands regularly, and frequently ventilating closed spaces. If you experience symptoms of the disease, avoid self-medication, seek medical attention, and do not return to work until you are fully recovered. Citizens are asked to refer only to official sources and not to believe or share unverified information circulating on social networks. Outbreak News Today is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. Subscribe
MAGA's attack on science is even worse than it looks
In my post on America’s 250-year anniversary, I argued that respect for the individual was the “secret sauce” in the U.S.’ long-lasting preeminence among nations. But it was certainly not the only factor. There were plenty of institutional innovations that helped the U.S. stay on top — economically, militarily, and in terms of the attractiveness of its society. One of these was American science. Today we take things like the modern research university, government grants for science, public-to-private research spinoffs, etc. for granted, but a lot of that infrastructure wasn’t there before World War 2. It was either invented or scaled up massively by the U.S. government in the postwar period, led by far-sighted scientist-bureaucrats like Vannevar Bush (pictured above). If you want to read about this history, a good place to start would be Jonathan Gruber and Simon Johnson’s excellent book Jump-Starting America. Those scientific institutions didn’t exist in a vacuum, however. They were backed by the U.S. government’s abiding faith in the power of science — and, even more fundamentally, by deep popular trust in the scientific enterprise. Science gave us radar and the atom bomb in wartime, and in peacetime it gave us plastics, vaccines, cheap food, and a thousand other things that made our lives easier. Science was also the driver behind American industry — chemicals, aerospace, telecommunications, computers, electronics, and so on. We owed science our jobs, our livelihoods, our comfortable living standards, and our greatness and power as a nation. It’s little wonder that both political parties, even as they fought viciously over other issues, were steadfast in their support of science. For a long time, the only people who distrusted science were a hippie fringe on the left who disliked modernity (or thought they did, anyway), who also disliked American industry and American power, and who subscribed to an early version of degrowth environmentalism. America’s scientific enterprise is still strong, especially compared to the systems in Europe, Japan, Korea, and other developed countries. It has lost a lot of ground to China in a relative sense, but a lot of that is because of China’s incredible growth; as China has poured untold amounts of money and talent into its research labs, spending and output have overtaken the U.S. by some measures. There are a few ways in which China’s rise creates problems for American science — for example, top scientists can choose to work in China instead of in the U.S. — and of course there’s the concern that China’s technological strength will help its military to reign supreme. But overall, China’s rise in science should be good for American science, since American scientists can use Chinese discoveries for free and build on them. The much bigger problem is that the scientific enterprise America built during and after World War 2 is now being threatened with absolute decline. The biggest problem, of course, is that much of the country — the Republican half — has basically lost faith in the scientific enterprise. To what degree this loss of faith is justified is an open question, and deserves to be discussed openly. But the larger point — that the system that powered American dominance is under threat — is true either way. Most Americans still trust science, but MAGA Republicans don’t There’s a myth, popular in right-wing circles, that scientists have lost the trust of regular Americans — either due to the increasingly left-wing composition of academic departments, or to misbehavior during Covid, or to DEI-related research taking over science, etc. This also fits with a wider narrative that Americans are losing trust in all of our institutions. But it just isn’t true. Poll after poll shows that on the whole, Americans still trust scientists and want to spend more on science. For example, here’s a Pew poll from late 2025 showing that although about a fifth of Republicans did lose confidence in science in 2020, two thirds still have at least “a fair amount” of confidence: That same poll found that scientists are among America’s most trusted groups — even better trusted than the military! In fact, Americans trust scientists more than people in most other countries do. Other polls show that although Republican trust in science has dropped somewhat, Republican support for spending more on science remains very strong: A Pew poll in 2023 found the exact same thing: So when MAGA types tell you about scientists losing their credibility, or a drop in trust in science, they’re only talking about themselves. Whatever left-wing politicization of science happened during the Biden administration — and there was definitely some of that — it was not enough to make most Republicans lose faith in the scientific enterprise, or favor research cuts in order to purge unwanted ideology from the system. That doesn’t mean I think progressives should continue down the path of politicizing scientific research. They should not, and Biden made real missteps in this area. Objectivity clearly matters for public trust of science in the long term. But as of right now, there’s no crisis of trust in science, except among the smallish minority of people who are running around screaming that there’s a crisis of trust in science. But despite science’s overwhelming popularity and public trust, Trump and his administration are launching an unprecedented and devastating attack on American science — cutting funding, and forcing science projects to undergo ideological review by government commissars. Trump’s comprehensive attack on science
Senate investigates what health officials knew about COVID-19 vaccine side effects
A Senate review led by Sen. Ron Johnson is examining how federal officials handled reports of possible COVID-19 vaccine side effects.
Pan American Health Organization warns of a ‘critical’ emergency after Venezuela’s earthquakes
The international agency says overcrowded shelters, vaccine shortages and a collapsing healthcare system threaten to spark disease outbreaks
Oregon pushes mpox vaccines as more serious type of virus spreads
Community transmission of a more serious type of mpox virus is increasing in several countries. Here's what health officials want Oregonians to know.
Is Anti-Vaxx Really Anti-Science?
It’s easy to blame vaccine skepticism on ignorance or scientific misinformation. But what if we took time to listen to some Americans’ since fears about vaccines?
She blamed flu shots for her twins’ deaths. Now she’s charged with murder.
Andrea Shaw, a plaintiff in a lawsuit against the American Academy of Pediatrics for recommending childhood vaccines, is accused of suffocating her daughter and son.
Former CDC official describes "pure chaos" as RFK Jr. sought to transform health agency and take over vaccine panel
Scientists find the “Achilles’ heel” of deadly gut bacteria
Researchers discovered an “Achilles’ heel” shared by E. coli, Shigella, and other diarrhea-causing bacteria: enzymes they use to breach the gut’s protective mucus layer. By targeting this common vulnerability, scientists may be able to develop a single vaccine that prevents several major diarrheal infections before they even begin.
Health officials confirm measles case in Larimer County teenager
Officials say the teenager, who had not received the MMR vaccine, was likely exposed during recent travel abroad.
Hiltzik: What does the GOP have against children?
The conservative war on child health starts with the anti-vaccine campaign and proceeds to cutbacks in nutrition assistance and narrowed access to healthcare.
Changing COVID-19 vaccine effectiveness against COVID-19 mortality in older adults in Australia, 2022-2025
Communications Health - Changing COVID-19 vaccine effectiveness against COVID-19 mortality in older adults in Australia, 2022-2025
Mississippi’s top health officer: Measles cases are ‘inevitable’ as county vaccination rates fall
Mississippi’s kindergarten vaccination rates declined during the most recent academic year, continuing a downward trend that began after the state started granting religious exemptions for school vaccine requirements.
Why a case pivotal to the anti-vax movement could end up at the Supreme Court
The legal argument that vaccine mandates without a religious exemption violate the First Amendment could deliver the anti-vaccine movement its biggest win.
Summer travel health: tips for heat exhaustion, insect bites and travel vaccines
Stay healthy while traveling with help from CVS Pharmacy and MinuteClinic. Get vaccines, refill prescriptions and prepare for summer travel risks.
Opinion: Proposed federal grant rules are attempt to ‘muzzle’ science | Harvard T.H. Chan School of Public Health
A proposed overhaul in how federal grants are awarded is aimed at shutting down scientific research on disfavored topics such as health disparities, climate change, gender identity, and vaccines, according to Harvard Chan School’s Nancy Krieger.
Would Hunters Take A Lyme Disease Vaccine? We Asked
By Bram Sable-Smith and KFF Health News HealthDay ReportersWEDNESDAY, July 1, 2026 (HealthDay News) — It’s tick season, possibly the worst in a decade. More and more Americans are being exposed to these parasites as climate change expands the range where they can survive. That means more people are also exposed to the bevy of health conditions they can ...
Claude Science is Here, Antibiotics Designed by Text Prompt Among Applications
Basecamp Research’s antibiotic design and vaccine prediction AI models are now available through Anthropic’s Claude Science.
Frequent AI chatbot use linked to belief in anti-vaccine myths, poll finds
Poll finds use of AI tools for health advice is correlated with belief in vaccine falsehoods, such as shots causing autism
Basecamp Research brings EDEN's antibiotic and vaccine design models to Claude Science
/PRNewswire/ -- Basecamp Research today announced that its antibiotic design and vaccine target prediction EDEN models are now available through Claude,...
Trump administration puts religious freedom at heart of US health policy
Critics say the new focus could reshape LGBTQ+ healthcare, abortion access and vaccine policy
KFF Tracking Poll on Health Information and Trust: Update on Common Vaccine Myths
This poll looks at exposure to and belief in several vaccine myths and finds that people without a trusted health care provider, and those who regularly use social media or AI for health information, are generally more likely than others to belief the false claims. It also analyzes belief across vaccine myths, showing the share of the public that are consistent myth believers, consistent myth deniers, and those who land in the "mixed middle."
Poll: People Without a Trusted Health Care Provider Are More Likely to Endorse Vaccine Myths, As Are Those Who Often Use Social Media or AI for Health Information
People who don’t have a trusted health care provider are more likely than people with one to believe or lean toward believing several common myths about vaccines, a new KFF Tracking Poll on Health Information and Trust reveals.
Vaccine Confidence Strategies and Emerging Vaccinology Science
With vaccine confidence top of mind for many infectious disease experts, the 2026 Annual Conference on Vaccinology Research covered communication challenges as well as the latest in vaccine science.
Supreme Court rejects legal battle over New York's COVID-19 vaccine mandate for healthcare workers
The dispute arose after New York's Department of Health issued an emergency rule that required healthcare workers to be fully vaccinated against COVID-19.
Your menstrual cycle may affect how well vaccines work
Women who were vaccinated against covid-19 in the luteal phase of their menstrual cycle reported having a breakthrough infection sooner than those vaccinated during their follicular phase
KATALIN KARIKÓ
She was met with resistance, got demoted and eventually forced to leave academia – but Katalin Karikó never lost focus, doubling-down on her work to harness mRNA for new vaccines and therapies. Karikó’s Nobel Prize-awarded discovery enabled the development of effective vaccines against COVID-19, offering protection to millions of people.
America's lifespan has doubled since 1776
U.S. life expectancy has doubled since 1776 thanks to vaccines, antibiotics, sanitation and clean water that reduced infectious disease deaths.
Lingering distrust, low vaccine rates threaten containment of Lancaster measles outbreak
LANCASTER, Pa. — A growing distrust of health professionals seems to be undermining their efforts in central and southeastern Pennsylvania to stop...
Free health clinic aims to expand care access on city's West Side
Free preventive care is coming to San Antonio’s West Side Saturday. The Health Collaborative’s Neighborhood Clinic offers 3D mammograms, screenings, vaccines, dental checks, food and help connecting to ongoing care.
If a Lyme disease vaccine gets approved, how would it go over? We asked hunters
Drugmakers are working on a potential new shot to prevent the tick-borne illness. How might it fare in the era of vaccine skepticism?
Making Our Own Luck
We are cross-posting a piece that former NIH official Kris Willis wrote for Macroscience. Kris is now the President and Founder of the Woodley Park Institute, for which I’m a board member. Picking winners or hedging bets? Federal science agencies have long wrestled with the question of how to ensure their billions of dollars of grants and contracts result in maximum benefits for Americans. On the surface, it might seem that a goal-oriented, interventionist style of management would be the best policy: prioritize our most pressing problems and distribute funding accordingly.This top-down strategy creates a unique hazard, though: bad choices can send resources in the wrong direction, resulting in slow progress that impedes the delivery of tangible benefits to citizens. Moreover, if decision makers pursue an applied advance when the underlying scientific principles remain poorly understood, they risk costly failures and a loss of support for the research enterprise at large. Examples include Nixon’s 1971 War on Cancer, undertaken on the premise that a cure could be achieved in less than a decade, the drive to build an operational commercial fusion plant by the mid-1990s, and the National Plan to Address Alzheimer’s Disease, which failed to produce the effective treatments and prevention strategies promised by 2025. The contrasting laissez-faire approach is to hedge your bets. If the path to an advance is impossible to predict, then the wisest choice might be to distribute funding to as widely as possible. The main risk of this strategy is that spreading funding thinly may limit the resources available to the most promising research, resulting in the same negative outcomes as the interventionist approach: limited support for the most promising topics, slow progress, and delayed returns. In reality, at science agencies like the National Science Foundation and National Institutes of Health, program managers navigate between these two extremes, setting some funds aside to target high-priority areas and using the rest to cover the widest possible range of meritorious proposals. This middle path seems like the most rational way to proceed, but it still requires making choices. How much should be set aside for high priority topics? What should those topics be? How should we define merit? Expert opinion can provide a helpful guide, but leading experts can have remarkably different opinions about what matters and what should be prioritized. Moreover, experts and administrators alike can be risk averse, giving an edge to high-profile, well-established concepts. What’s really needed is a data-driven framework to help guide decision-making, one that doesn’t simply repackage prestige or incumbency. Recognizing breakthroughs years in advance Many breakthroughs fail to attract funding or recognition at the earliest stages of development. Katalin Karikó, for example, spent years struggling to win grants for work on mRNA that would eventually win her and Drew Weissman a Nobel Prize. Similar stories can be told about Jim Allison’s groundbreaking studies leading to the development of cancer immunotherapy, Stan Pruisner’s demonstration that prions can self-replicate without DNA, or Robin Warren and Barry Marshall’s proof that Helicobacter pylori, not stress, causes ulcers. Yet at some point, the scientific community recognizes and responds to transformative breakthroughs like these. How does that change happen? And what if science funders could identify the areas that are on the cusp of a breakthrough? Those questions led my collaborators and me to study how scientists responded to past breakthroughs. Based on patterns in that data, we developed a means of predicting future breakthroughs, using biomedicine as a proof of concept. It’s worth taking a moment to describe how our approach works. Briefly, our prediction process begins by grouping the 18 million or so peer-reviewed papers in PubMed, the authoritative database of biomedical research, into roughly 50,000 unique topics. A small subset of these topics are so widely acclaimed as breakthroughs that they have been recognized with a major prize like a Nobel or a Lasker Award. We theorized that studying the development of these outliers over time, especially before they gained acclaim, was the key to identifying future instances of them. After defining topics, we chose 21 representative breakthroughs and asked what they looked like before they won prestigious prizes. To answer that question, we re-ran our topic-mapping algorithm repeatedly, winding back the clock one year each time, stringing together the years to follow the progress of each field as it grew and advanced. We found that in each case, the years leading up to a discovery followed a pattern: a burst of papers on a new, rapidly evolving topic, many of which quickly became influential. These characteristics—the percent of papers that are new, the percentage of papers that are brought in from other topics, and the influence of each individual paper—can all be measured separately for any given topic. Together, they act as a predictive signal that is detectable an average of five years before a transformative discovery is made, and up to thirty years before the discovery receives a major prize. Scanning the current research landscape for topics that display this signal allows us to predict what work will likely produce a future breakthrough. Each year we analyzed includes four or five signals, a number that appears to have remained constant across a twenty year time frame. In their classic work on the sociology of science, Bruno Latour and Steve Woolgar established that the desire to participate in a major discovery is an important motivator for scientists as they consider whether they should take up (or abandon) a research problem. Although further work is needed, the simplest explanation for our results is that this behavior is widespread enough to detect at scale. A foundational advance, or something like it, draws the attention of scientists and causes them to change the direction of their research. They vote with their feet, staking their own reputation and careers by publishing on and citing the new idea. That upswell of interest is the foundation of our breakthrough signal. What kind of research does our model identify as a breakthrough? After building a model based on the patterns in our 21 preselected breakthroughs, we tested it by identifying all early signals of discovery from 1994 through 1997. Of the 18 signals we found in that time period, 17 can be traced forward in time to a breakthrough. Examples include super-resolution fluorescence microscopy (see the image above), the directed evolution of proteins and enzymes (Chemistry Nobel, 2018), and sequencing the human genome (National Medal of Science, 2008). The discovery of the role of leptin signaling in obesity is a particularly interesting case study. Around 1950, scientists noticed the existence of a type of lab mouse that suffered from a unique inherited form of obesity. When given the freedom to choose their own diet, these mice ate more than normal and preferred food that was high in fat. Researchers had few clues as to why the animals overate; early experiments pointed to the existence of a soluble ob factor found circulating in the bloodstream that regulated appetite, but its identity was unknown. In 1994, Jeffrey Friedman and colleagues identified and sequenced the ob gene, noting that the protein it encoded appeared to fit the profile of a circulating factor. A year later, a trio of high-profile publications demonstrated that ob was a hormone that regulated body weight and fat deposition by regulating appetite. One of these was co-authored by Friedman, who christened it leptin from the ancient Greek word for thin. Using our model, the data from 1996 make it clear this advance would become a breakthrough. Scientists had flocked to study the biology of the new hormone, generating the flurry of new papers and citations required to produce a signal. One of these demonstrated that serum leptin concentrations reflected the amount of adipose tissue in the human body, providing clinical validation of the earlier mouse studies. Before the identification of leptin, scientists were unable to point to a specific molecule that controlled appetite and adiposity, so that it was impossible to rule out non-physiological causes of obesity; its characterization fundamentally changed our concept of weight gain. In 2010, Friedman and fellow pioneer Douglas Coleman were awarded a Lasker for the discovery. Our work also identifies breakthroughs in clinical practice and behavioral and social sciences, even though these areas are less likely to draw the attention of major prize committees. One example that falls into this category is the introduction of endovascular aneurysm repair, a minimally invasive surgical procedure for the treatment of abdominal aortic aneurysm, a leading cause of death among Americans over the age of 65. Relative to the previous standard of care, it reduces in-hospital mortality by almost four-fold. In 2017, Timothy Chuter received the American College of Surgeons’ prestigious Jacobsen Innovation award for his multiple refinements to the technique. Another under-recognized breakthrough identified by our model is the development of standardized survey instruments to assess the quality of life for HIV+ patients. The antiretroviral cocktails introduced in the mid-1990s reduced AIDS mortality, but treatment came with serious side effects. The new evaluations showed that patients whose disease progressed had worse physical functioning than Americans with other chronic diseases, while those who were asymptomatic maintained a health-related quality of life on par with the overall US population. This evidence made it possible for patients and activists to argue that even in the absence of a total cure, and in spite of the side effects, alleviation of symptoms was a worthwhile priority for clinicians. My colleagues and I have failed to identify any significant recognition for the physicians and health policy experts who pioneered this advance, although in 2016, researchers called for the World Health Organization to set targets for good health-related quality of life as part of its framework to end the AIDS pandemic. From forecasting to funding How should science funders use our predictions? Any serious discussion of what we should do with this new capability needs to begin with an understanding of its limitations. We can’t (and shouldn’t) invest all of our resources in the small number of topics predicted to produce breakthroughs. Innovative new fields are born from existing ones; they rarely arise de novo. If funders don’t maintain a diverse portfolio, the breakthroughs of tomorrow will have no antecedents. Think of this as eating the seed corn, or killing the goose that lays the golden egg. There are also multiple goals of funding beyond basic scientific discovery, including translating discoveries into clinical practice, developing new technologies, supporting economic development, and training new scientists. The investments needed to accomplish these goals are likely different from those required to support emerging breakthroughs. Finally, we must be aware that we may not capture every instance of a breakthrough. The concept is fuzzy, and not every significant discovery is recognized with a major award. Further, breakthroughs are rare, meaning that our dataset is, by necessity, small. This makes formal estimates of accuracy challenging. Although our overall success rate appears to be high, any one signal may turn out to be a false positive. We found one apparent example: the development of the third generation COX-2 inhibitors, Vioxx and Celebrex, which were much celebrated in the early 2000s as effective but non-addictive pain relievers, meets all the algorithmic criteria of a breakthrough. Five years after it received FDA approval, researchers demonstrated that Vioxx was associated with serious cardiovascular complications, and the manufacturer voluntarily pulled the drug from the market. Celebrex remains available, although like other NSAIDs, it carries an FDA warning for increased cardiovascular risk. Decision makers who were overly focused on the breakthrough potential of this research might have wasted substantial resources nurturing an area that ultimately proved to be a failure—but so would those who relied on expert opinion at the time. That said, the potential benefits of funding the next mRNA vaccine or cancer immunotherapy years earlier than we might have are large. When we can’t assume the outcome of an action, it’s worth conducting an experiment. Can targeted support for areas that are poised to produce a breakthrough increase the return on scientific investment without cannibalizing future advances? With the necessary administrative infrastructure in place, conducting this experiment would be straightforward. First, identify all the breakthrough signals between 2018 and 2023, select half at random, and commit to a decade of investment. For biomedicine, a six year window should yield about 30 topics with the potential to produce a breakthrough. Providing strong support to half of these might be accomplished for $300 million a year. That’s roughly half of the recent annual budget of the NIH Common Fund or around 20% of the fiscal year 2025 budget for ARPA-H. After five years, then again at ten, compare to see which group — the one that was actively managed, or the control — produced more breakthroughs, and on what timescale. Although we used biomedicine as an example, the same experiment could just as well be run for physics, materials science, or any other discipline. Any attempt to undertake such an experiment should keep three points top of mind. First, we can predict the topic of future breakthroughs, but the people and vision for how to move the work forward are still important. In practice, this means success requires active program managers with the expertise to develop the science and the authority to do so, including by recruiting investigators. Second, we would be wise to learn from the failures of past attempts to fund transformative research. High among these are funding modestly repackaged work, confusing the genuinely novel with the merely unfamiliar, and relying too much on incumbent investigators. All of these risks can be mitigated by thoroughly and intelligently integrating high quality data into portfolio management. Finally, we need to have patience. Even with strong funding support, producing a breakthrough takes time. If supporting breakthroughs is the best way to nurture the birth of new fields, we also need to accurately describe and properly manage the other two stages, so that we invest wisely throughout the productive lifetime of ideas and divest once they reach the point of diminishing returns. We would benefit from more study of all of these phases, especially the transition from one to another. More research could answer questions like: When does a breakthrough become an established field? How do the availability of funding, the size and characteristics of the available workforce, and the accumulation of evidence that disagrees with prevailing models affect a field’s decline? Exactly how do old ideas give birth to new ones, and can we speed up the process? The more we understand about the dynamics of scientific progress, the better we can maximize the odds that our curiosity leads to results. I’d call that finding a way to make our own luck.
Ebola response highlights value of African science
With African scientists leading the way in the latest Ebola response, Catherine Kyobutungi makes the case for long-term investment.
Bacteria-killing viruses redirect vaccine immunity to destroy cancer
Phages, viruses that infect bacteria, could be genetically manipulated to destroy cancerous cells using the immunity we have acquired from vaccines
Latest COVID booster may offer bonus health benefit, study suggests
The latest COVID-19 vaccine (2024-2025) has been linked to fewer serious heart-related events among U.S. veterans. New research confirmed a small reduction in COVID-related cardiovascular events, or COVID-19-associated MACE, due to the vaccine.
Covid vaccine study the acting CDC director blocked is published in an outside journal
The findings suggest that Covid vaccines reduced the likelihood of severe illness last fall and winter.
CDC’s chief blocked a covid vaccine study. Now it’s in a top medical journal.
The study found that the vaccine reduced the risk of emergency department visits and hospitalizations among healthy adults by about half last winter.
New Vaccine Clinics - Cabell-Huntington Health Department
FOR IMMEDIATE RELEASE June 23, 2026 Cabell-Huntington Health Department Continues After-Hours Vaccine Clinics through Summer Months Huntington, WV – The Cabell-Huntington Health Department (CHHD) will offer two evening vaccine clinics […]
Air Force base hit with flu outbreak sickening over 160
Presented by Philip Morris International{beacon} Health Care Health Care PRESENTED BY The Big Story Air Force base hit with flu outbreak sickening over 160 More than 160 troo…
New First-of-Its-Kind Flu Vaccine Approved by FDA Expert Panel
This could prevent thousands of hospitalizations.
The Healthcare Leaders Shaping Tomorrow – and the Challenges Facing Them
Healthcare innovation is advancing at a pace few could have imagined decades ago, from gene-editing therapies and lifesaving vaccines to artificial intelligence systems that could transform how doctors diagnose and treat disease. But at a time of unprecedented scientific progress, industry leaders ...
In DRC, fighting Ebola means fighting misinformation
The Africa Centres for Disease Control and Prevention warns this strain of the Ebola virus may be the worst on record. There is no vaccine, and misinformation is rampant, as many people simply do not believe Ebola is real.
FDA panel considers first-of-its-kind flu vaccine using mRNA technology
The FDA advisory panel is meeting Thursday to consider it
FDA panel considers first-of-its-kind flu vaccine using mRNA technology
The FDA advisory panel is meeting Thursday to consider it
Science, Public Health, and the Politics of Truth
Presented as part of the McCloskey Speaker Series.Peter Hotez, M.D., Ph.D., professor and dean of the National School of Tropical Medicine at Baylor College of Medicine, joins the Aspen Institute for a keynote lecture on the intersection of science, medicine, and public trust. A leading authority on vaccines and neglected tropical diseases, Hotez reflects on the challenges facing public health today, the growing politicization of science, and what it will take to rebuild trust in scientific institutions in the years ahead.Paepcke Auditorium, doors at 5:00 pmRegistrationThis event is free and open to the public, but registration is required, and capacity is established on a first-come, first-served basis. Once an event is at capacity, we will have an in-person waitlist at the door.Public registration is now open for summer 2026. Please click here to register.ParkingParking is very limited. Please carpool, walk, bike, or ride RFTA.Book signing will immediately follow the event. To learn more about his book or to order a copy, please click here.
Science, Public Health, and the Politics of Truth
Presented as part of the McCloskey Speaker Series.Peter Hotez, M.D., Ph.D., professor and dean of the National School of Tropical Medicine at Baylor College of Medicine, joins the Aspen Institute for a keynote lecture on the intersection of science, medicine, and public trust. A leading authority on vaccines and neglected tropical diseases, Hotez reflects on the challenges facing public health today, the growing politicization of science, and what it will take to rebuild trust in scientific institutions in the years ahead.Paepcke Auditorium, doors at 5:00 pmRegistrationThis event is free and open to the public, but registration is required, and capacity is established on a first-come, first-served basis. Once an event is at capacity, we will have an in-person waitlist at the door.Public registration is now open for summer 2026. Please click here to register.ParkingParking is very limited. Please carpool, walk, bike, or ride RFTA.Book signing will immediately follow the event. To learn more about his book or to order a copy, please click here.
EU supports ebola response with €493 million in vaccines, treatment and health aid
The European Commission said on Wednesday it will fund the response to the ebola outbreak in Central Africa with a €493 million ($572 million) financial aid package.
Summer Travel Health Checklist
Planning a summer trip? Learn 7 expert tips to help stay healthy while traveling, including measles prevention, travel vaccines, food safety, and more.
Health 'War Room,' Digital Tools Are Tracking Disease Risks During World Cup
Public health experts address the logistical challenge of tracking the health and location of players and fans across 16 World Cup host cities.